{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:28:37Z","timestamp":1786649317063,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the outcome and ocular adverse events of bedside bilateral sequential intravitreal anti-vascular endothelial growth factor injections for retinopathy of prematurity (ROP) (BBSIR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective interventional study included infants who received BBSIR with a follow-up of at least 1 month. Clinical history, intravitreal injection details, indications, intraoperative and postoperative ocular adverse events, and outcomes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The study cohort included 192 babies (384 eyes) spread over 9 years. The mean gestational age was 30.2 \u00b1 2.6 weeks (28.8\u201334.1), and the birth weight was 1098.11 \u00b1 271.65 g (650\u20132000). The indications for BBSIR were as follows: 73.4% (n = 141 infants) were too sick to transfer to an ophthalmic unit, 10.9% (n = 21 infants) due to the parents\u2019 inconvenience of traveling to the ophthalmic center, and 15. 6% (n = 30 infants) due to both reasons. The injections were given by an ROP specialist\/ROP-trained ophthalmologist after due parental consent, considering each eye as a fresh eye with separate scrubbing and draping. Light from the head-worn indirect ophthalmoscope served as the source of illumination. The retinopathy was regressing\/regressed in 92.4% of babies until the last follow-up. The major ocular complication was cataract in 2 eyes (0.5%). There was no incidence of endophthalmitis till last follow-up (median 5.7 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>As per this study, BBSIR was observed to be effective and safe if given by those fully trained in the management of ROP. Though the rate of complications like cataract is small, they can pose management challenges and impact vision in a growing child.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_558_24","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T03:06:50Z","timestamp":1726024010000},"page":"S112-S118","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Bedside bilateral sequential intravitreal anti-VEGF injections for retinopathy of prematurity"],"prefix":"10.4103","volume":"73","author":[{"given":"Priya","family":"Bajgai","sequence":"first","affiliation":[{"name":"Vitreoretinal Services, Nepal Eye Institute, Kathmandu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susree","family":"Satavisa","sequence":"additional","affiliation":[{"name":"Anant Bajaj Retina Institute, L V Prasad Eye Institute (Mithu Tulsi Chanrai Campus), Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taraprasad","family":"Das","sequence":"additional","affiliation":[{"name":"Anant Bajaj Retina Institute, Srimati Kannuri Santhamma Centre for Vitreoretinal Diseases, L V Prasad Eye Institute (Kallam Anji Reddy Campus), Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhadra","family":"Jalali","sequence":"additional","affiliation":[{"name":"Anant Bajaj Retina Institute, Srimati Kannuri Santhamma Centre for Vitreoretinal Diseases, L V Prasad Eye Institute (Kallam Anji Reddy Campus), Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balakrushna","family":"Samanataray","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Srirama Chandra Bhanja Medical College and Hospital, Cuttack, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameera","family":"Nayak","sequence":"additional","affiliation":[{"name":"Vitreoretinal Services, Anant Bajaj Retina Institute, L V Prasad Eye Institute (Kode Venkatadri Chowdary Campus), Vijayawada, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapas Ranjan","family":"Padhi","sequence":"additional","affiliation":[{"name":"Vitreoretinal Services, Grewal Eye Institute, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"R1-20260424","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.clp.2014.08.011","article-title":"Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity","volume":"41","author":"Hartnett","year":"2014","journal-title":"Clin Perinatol"},{"key":"R2-20260424","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.oret.2019.11.015","article-title":"Characterization of the progression pattern in retinopathy of prematurity subtypes","volume":"4","author":"Fukushima","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R3-20260424","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.survophthal.2018.04.002","article-title":"Retinopathy of prematurity: A review of risk factors and their clinical significance","volume":"63","author":"Kim","year":"2018","journal-title":"Surv Ophthalmol"},{"key":"R4-20260424","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archopht.1995.01100040089032","article-title":"Correlation of retinopathy of prematurity in fellow eyes in the cryotherapy for retinopathy of prematurity study. The cryotherapy for retinopathy of prematurity cooperative group","volume":"113","author":"Quinn","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"R5-20260424","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1007\/s00417-023-06108-y","article-title":"The ideal intravitreal injection setting: Office, ambulatory surgery room or operating theatre? A narrative review and international survey","volume":"261","author":"Veritti","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-20260424","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"R7-20260424","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaophthalmol.2021.3096","article-title":"Safety of receiving anti-vascular endothelial growth factor intravitreal injection in office-based vs operating room settings: A meta-analysis","volume":"139","author":"Li","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"R8-20260424","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000499115","article-title":"Same-day bilateral intravitreal anti-vascular endothelial growth factor injections: Experience of a large Canadian retina center","volume":"242","author":"Juncal","year":"2019","journal-title":"Ophthalmologica"},{"key":"R9-20260424","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2018.06.022","article-title":"Endophthalmitis rates after bilateral same-day intravitreal anti-vascular endothelial growth factor injections","volume":"194","author":"Borkar","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R10-20260424","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"key":"R11-20260424","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"R12-20260424","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: The FIREFLEYE randomized clinical trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"R13-20260424","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.4103\/ijo.IJO_200_21","article-title":"Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society","volume":"69","author":"Gangwe","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R14-20260424","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.ophtha.2016.04.033","article-title":"Immediate sequential bilateral pediatric vitreoretinal surgery: An International multicenter study","volume":"123","author":"Yonekawa","year":"2016","journal-title":"Ophthalmology"},{"key":"R15-20260424","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R16-20260424","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R17-20260424","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of bevacizumab use in patients with retinopathy of prematurity: A multicenter study in Taiwan","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology"},{"key":"R18-20260424","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/jop.2011.0060","article-title":"Intravitreal bevacizumab for retinopathy of prematurity","volume":"27","author":"Harder","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"R19-20260424","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","article-title":"Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey","volume":"253","author":"Yetik","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R20-20260424","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: Comparison between Ranibizumab and Bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"key":"R21-20260424","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jaapos.2008.02.012","article-title":"Retinopathy of prematurity care: Patterns of care and workforce analysis","volume":"12","author":"Kemper","year":"2008","journal-title":"J AAPOS"},{"key":"R22-20260424","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40942-020-00276-3","article-title":"Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors","volume":"7","author":"Bazvand","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"R23-20260424","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3928\/01913913-20190211-02","article-title":"Iatrogenic crystalline lens injury in pediatric eyes following intravitreal injection for retinopathy of prematurity","volume":"56","author":"Vanathi","year":"2019","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R24-20260424","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.3928\/01913913-20190219-02","article-title":"Bilateral total cataract after intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity","volume":"56","author":"Khokhar","year":"2019","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R25-20260424","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.3892\/etm.2017.4406","article-title":"Early clinical characteristics of bacterial endophthalmitis in retinopathy of prematurity after intravitreal bevacizumab injection: A case report","volume":"13","author":"Wang","year":"2017","journal-title":"Exp Ther Med"},{"key":"R26-20260424","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/ICB.0000000000001220","article-title":"results of two cases with distinct complications due to intravitreal bevacizumab in retinopathy of prematurity","volume":"17","author":"Yalcinbayir","year":"2023","journal-title":"Retin Cases Brief Rep"},{"key":"R27-20260424","doi-asserted-by":"crossref","first-page":"967","DOI":"10.4103\/ijo.IJO_884_17","article-title":"Post-ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity","volume":"67","author":"Chandra","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R28-20260424","first-page":"8861435","article-title":"Endophthalmitis in retinopathy of prematurity after intravitreal aflibercept injection","volume":"2020","author":"Suren","year":"2020","journal-title":"Case Rep Ophthalmol Med"},{"key":"R29-20260424","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.1016\/j.jaapos.2019.08.202","article-title":"Richards, Alan B. Bilateral endophthalmitis from bevacizumab intravitreal injections in type I retinopathy of prematurity","volume":"23","author":"So","year":"2019","journal-title":"J AAPOS"},{"key":"R30-20260424","first-page":"65","article-title":"Consensus on the intravitreal injection technique among infants with retinopathy of prematurity by the vitreo-retina society of the Philippines","volume":"45","author":"Loy","year":"2020","journal-title":"Philipp J Ophthalmol"}],"updated-by":[{"DOI":"10.4103\/ijo.ijo_2278_24","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000}}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_558_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:52:24Z","timestamp":1786647144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_558_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":30,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_558_24","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"2024-03-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}